(2,4-Dichloro-pyridin-3-yl)-phenyl-methanol | 134031-17-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (2,4-Dichloro-pyridin-3-yl)-phenyl-methanol
• 英文别名: (2,4-Dichloropyridin-3-yl)(phenyl)methanol；(2,4-dichloropyridin-3-yl)-phenylmethanol
• CAS: 134031-17-7
• 化学式: C₁₂H₉Cl₂NO
• 分子量: 254.116
• InChiKey: AGIHVOLVUBJMKI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2,4-Dichloro-pyridin-3-yl)-phenyl-methanol 在 chromium(VI) oxide 作用下， 以 丙酮 为溶剂， 反应 0.17h， 生成 (2,4-二氯吡啶-3-基)(苯基)甲酮
  参考文献：
  名称：

  Lithiation of polychloropyrimidines and dichloropyridines

  摘要：

  DOI：

  10.1021/jo00015a041
• 作为产物：
  描述：

  2,4-二氯吡啶 、 苯甲醛 在 lithium diisopropyl amide 作用下， 生成 (2,4-Dichloro-pyridin-3-yl)-phenyl-methanol
  参考文献：
  名称：

  Lithiation of polychloropyrimidines and dichloropyridines

  摘要：

  DOI：

  10.1021/jo00015a041

文献信息

• [EN] AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDRS<br/>[FR] DERIVES AZETIDINECARBOXAMIDE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES A MEDIATION DU RECEPTEUR DU CB1
  申请人：VERNALIS RES LTD

  公开号：WO2004096794A1

  公开（公告）日：2004-11-11

  Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors, such as obesity, wherein: R1 is aryl or heteroaryl; R2 is alkyl, aryl or heteroaryl; R3 is alkyl, aryl, heteroaryl, NR9R10, OR 15, or NR 16C(O)R17; Y is C=O, C=S, SO2, or (CR7R8)p; m = 1 or 2; n = 1 or 2; and p=1,2,3 or 4, R7 to R17 being as defined in the specification; wherein if -Y-R3 is -C(O)NH(alkyl) then: R1 and/or R2 is selected from heteroary1; and/or m and/or n is 2; and/or R11 and/or R12 is lower alkyl, or a pharmaceutically acceptable salt or prodrug thereof.

  化合物的化学式（I）及其在治疗中的应用，特别是用于治疗由CB1受体介导的疾病，如肥胖，其中：R1为芳基或杂环芳基；R2为烷基，芳基或杂环芳基；R3为烷基，芳基，杂环芳基，NR9R10，OR 15，或NR 16C(O)R17；Y为C=O，C=S，SO2，或（CR7R8）p；m = 1或2；n = 1或2；p=1,2,3或4，R7到R17如规范中定义；其中如果-Y-R3为-C(O)NH(烷基)则：R1和/或R2从杂芳基中选择；和/或m和/或n为2；和/或R11和/或R12为较低烷基，或其药用盐或前药。
• Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs
  申请人：Davidson Edward Paul James

  公开号：US20070173486A1

  公开（公告）日：2007-07-26

  Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB 1 receptors, such as obesity, wherein: R 1 is aryl or heteroaryl; R 2 is alkyl, aryl or heteroaryl; R 3 is alkyl, aryl, heteroaryl, NR 9 R 10 , OR 15 , or NR 16 C(O)R 17 ; Y is C═O, C═S, SO 2 , or (CR 7 R 8 ); m=1 or 2; n=1 or 2; and p=1, 2, 3 or 4, R 7 to R 17 being as defined in the specification; wherein if —Y—R 3 is —C(O)NH(alkyl) then: R 1 and/or R 2 is selected from heteroaryl; and/or m and/or n is 2; and/or R 11 and/or R 12 is lower alkyl, or a pharmaceutically acceptable salt or prodrug thereof.

  式(I)的化合物及其在治疗中的用途，特别是用于治疗由CB1受体介导的疾病，例如肥胖症，其中：R1为芳基或杂环芳基；R2为烷基，芳基或杂环芳基；R3为烷基，芳基，杂环芳基，NR9R10，OR15或NR16C（O）R17；Y为C═O，C═S，SO2或（CR7R8）；m=1或2；n=1或2；p=1、2、3或4，R7到R17如规范所定义；如果—Y—R3为—C（O）NH（烷基），则：R1和/或R2选自杂环芳基；和/或m和/或n为2；和/或R11和/或R12为较低的烷基，或其药学上可接受的盐或前药。
• Heterocyclic Compounds and Methods of Use
  申请人：MEDIVATION TECHNOLOGIES, INC.

  公开号：US20160272645A1

  公开（公告）日：2016-09-22

  The present application discloses compounds that are inhibitors of Btk, compounds that are inhibitors of PI3Kδ, and compounds that are dual inhibitors of both Btk and PI3Kδ. Also described are methods for synthesizing such inhibitors and methods for using such inhibitors for the treatment of diseases wherein inhibition of Btk and PI3Kδ provides a therapeutic benefit to a patient having the disease.

  本申请公开了抑制Btk的化合物、抑制PI3Kδ的化合物以及同时抑制Btk和PI3Kδ的双重抑制剂化合物。还描述了合成这些抑制剂的方法和使用这些抑制剂治疗疾病的方法，其中抑制Btk和PI3Kδ对于患有该疾病的患者提供治疗效益。
• Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders
  申请人：Davidson James Edward Paul

  公开号：US20090181939A1

  公开（公告）日：2009-07-16

  Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB 1 receptors, such as obesity, wherein: R 1 is aryl or heteroaryl; R 2 is alkyl, aryl or heteroaryl; R 3 is alkyl, aryl, heteroaryl, NR 9 R 10 , OR 15 , or NR 16 C(O)R 17 ; Y is C═O, C═S, SO 2 , or (CR 7 R 8 ) p ; m=1 or 2; n=1 or 2; and p=1, 2, 3 or 4, R 7 to R 17 being as defined in the specification; wherein if —Y—R 3 is C(O)NH(alkyl) then: R 1 and/or R 2 is selected from heteroaryl; and/or m and/or n is 2; and/or R 11 and/or R 12 is lower alkyl, or a pharmaceutically acceptable salt or prodrug thereof.

  公式（I）的化合物及其在治疗中的应用，特别是用于治疗由CB1受体介导的疾病，如肥胖症，其中：R1为芳基或杂环芳基；R2为烷基，芳基或杂环芳基；R3为烷基，芳基，杂环芳基，NR9R10，OR15或NR16C（O）R17；Y为C═O，C═S，SO2或（CR7R8）p；m=1或2；n=1或2；p=1、2、3或4，R7至R17如规范中所定义；其中，如果—Y—R3为C（O）NH（烷基），则：R1和/或R2选择自杂环芳基；和/或m和/或n为2；和/或R11和/或R12为低碳烷基，或其药学上可接受的盐或前药。
• EP1618105A1
  申请人：——

  公开号：EP1618105A1

  公开（公告）日：2006-01-25